Ian joined Advent in 2012 with an international career in Life Sciences. He is currently serving as CBO of Advent portfolio company Eloxx Pharmaceuticals, Inc. and before that he was CEO of the portfolio company, F2G Limited, a leading late-stage antifungal organisation.
Earlier in his career, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US.
Ian has held a variety of senior commercial positions with Chroma Therapeutics Ltd.,Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently is Non-Executive Chairman of Bioventix plc (an AIM-quoted company) and is a member of the Board of Trustees at LifeArc. Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University. Ian has been an advisor to several Advent portfolio companies including Amphista and NeRRe Therapeutics.